These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 16513529)

  • 1. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.
    Carpenter SL; Khair K; Gringeri A; Valentino LA
    Haemophilia; 2018 Jul; 24(4):570-577. PubMed ID: 29901839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
    Ishiguro A
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we treat a hemophilia A patient with a factor VIII inhibitor.
    Kempton CL; White GC
    Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
    Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
    Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
    J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
    Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
    Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of immune tolerance induction in hemophilia A.
    Schep SJ; Schutgens REG; Fischer K; Boes ML
    Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors in patients with haemophilia A.
    Kreuz W; Ettingshausen CE
    Thromb Res; 2014 Nov; 134 Suppl 1():S22-6. PubMed ID: 24745722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of factor VIII inhibitors.
    Sultan Y; Algiman M
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):193-9. PubMed ID: 2130931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.